Pipeline
Ganaxolone, through its validated GABAA mechanism, has opportunities in orphan indications and in chronic and acute care settings.
Clinical Trial Information
Ganaxolone is being developed in intravenous (IV) and oral formulations intended to maximize therapeutic reach to patient populations in both acute and chronic care settings.
Marinus is currently conducting studies in CDKL5 deficiency disorder, PCDH19-related epilepsy, and refractory status epilepticus.
SE is an emergency condition of continuous seizures lasting more than 5 minutes. Ganaxolone Phase 3 study initiated in Q3 2020 with topline data expected 1H 2020. Trial info
MAA Q3 2021
CDD is a rare genetic disorder resulting in developmental delay, intellectual disability, visual impairment, and severe epilepsy. Positive Phase 3 data reported in September 2020. Open label extension study is on-going. Trial info
TSC is a genetic disorder resulting in benign tumors, cognitive impairment, behavioral problems, and refractory epilepsy. Phase 2 topline data expected mid-2021. Trial Info
PCDH19-related epilepsy is a genetic disorder leading to psychiatric problems, neurodevelopmental delays, and refractory seizures often occurring in clusters. Phase 2 placebo-controlled data, stratified by a potential biomarker, are expected 1H-2021. Trial info
* Program on hold pending decision to conduct additional trials